Particle.news
Download on the App Store

States and Hospitals Rebuke ACIP Move to Delay Newborn Hepatitis B Shot

The CDC has not finalized the panel’s vote, leaving many providers to maintain birth‑dose policies.

Overview

  • ACIP voted 8–3 to end the universal hepatitis B dose at birth and to defer vaccination until at least two months for infants of mothers who test negative, a change that requires adoption by acting CDC director Jim O’Neill.
  • Five major Michigan systems — McLaren, Munson, Henry Ford Health, Corewell Health and University of Michigan Health — say they will keep offering the birth dose, echoing pledges by other providers and states to retain current practice.
  • Forty‑four medical and professional groups, including the American Medical Association and American Academy of Pediatrics, have publicly opposed the new guidance and urged continuation of universal newborn vaccination.
  • Public‑health experts warn that relying on maternal screening could miss infected mothers because hepatitis B tests can produce 2%–3% false negatives, putting newborns at risk if the birth dose is deferred.
  • President Donald Trump directed HHS and the CDC to review vaccine schedules in peer countries, a comparison experts say is not applicable to the U.S. system; ACIP has also moved to split the combined MMRV shot, signaling broader shifts in federal guidance.